Overview

Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-09-10

Target enrollment:

Participant gender:

Summary

This is a Phase 1b, randomized, open-label, active-controlled, parallel, multiple-dose study comparing the safety, pharmacokinetics and efficacy of DehydraTECH Cannabidiol and Glucagon-like Peptide 1 (GLP-1) agonists alone and in combination, in overweight or obese, pre- and type 2 diabetic participants.

Phase:

PHASE1

Details

Lead Sponsor:

Lexaria Bioscience Corp.

Treatments:

semaglutide
Single Person